Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus kefiranofaciens ZW18
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus kefiranofaciens ZW18 is a probiotic strain whose postbiotic derivatives (referred to as Post18) are being investigated for their therapeutic potential in treating hepatocellular carcinoma (HCC). The postbiotic contains bioactive compounds such as cyclic di-GMP (c-di-GMP) and 3-hydroxybutyric acid, which possess anticancer properties. Preclinical studies demonstrate that Post18 effectively inhibits HCC cell proliferation and migration while inducing apoptosis. Its mechanism of action involves modulating the tumor microenvironment by enhancing the infiltration of CD4+ and CD8+ T lymphocytes and elevating the production of pro-inflammatory cytokines like interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α). Additionally, it reduces the presence of immunosuppressive regulatory T cells (Tregs) and promotes a beneficial gut microbiota profile that increases the production of short-chain fatty acids (SCFAs), particularly butyric acid, which further contributes to its antitumor effects.
- Other names
- L. kefiranofaciens ZW18
Beyond the preview
Go deeper on Lactobacillus kefiranofaciens ZW18.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus kefiranofaciens ZW18.